When Recell gets approved in Japan, I wonder if Avita can use the data that it will accumulate from Japanese patients that are treated for vitiligo, diabetic foot ulcers and venous leg ulcers, to speed up the U.S. FDA approval process for those treatments?
News 
Market Data 
Discover 
